研究スタッフ

[公開日] 2020年3月11日 [最終更新日] 2023年8月30日

全人的ながん診療

須藤 一起

医員(乳腺・腫瘍内科医員・希少がんセンター 併任)

専門医・認定医資格など

日本外科学会 外科専門医
日本内科学会 認定内科医
日本臨床腫瘍学会 がん薬物療法専門医

座右の銘 一隅を照らす
出身地 東京都
趣味 ラグビー
将来の目標 がんで苦しむ人を減らす
患者さんへ一言 一緒に最善の治療を考えましょう。

須藤 一起の代表的な論文

  1. Iwasa S, Koyama T, Nishino M, Kondo S, Sudo K, Yonemori K, Yoshida T, Tamura K, Shimizu T, Fujiwara Y, Kitano S, Shimomura A, Sato J, Yokoyama F, Iida H, Kondo M, Yamamoto N. First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors. Cancer Sci. 2023 Jan;114(1):211-220.
  2. Abe S, Matsuzaki J, Sudo K, Oda I, Katai H, Kato K, et al. A novel combination of serum microRNAs for the detection of early gastric cancer. Gastric Cancer. 2021;24(4):835-43.
  3. Sudo K, Kato K, Matsuzaki J, Takizawa S, Aoki Y, Shoji H, et al. Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab. Japanese Journal of Clinical Oncology. 2020;50(2):114-21.
  4. Sudo K, Kato K, Matsuzaki J, Boku N, Abe S, Saito Y, et al. Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling. JAMA network open. 2019;2(5):e194573-e.
  5. Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, et al. A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. Clinical Pharmacology & Therapeutics. 2019.
  6. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. Journal of Clinical Oncology. 2014;32(30):3400.
  7. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer research. 2014;74(15):4170-82.
  8. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, et al. ALDH‐1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Molecular oncology. 2014;8(1):142-9.
  9. Sudo K, Taketa T, Correa AM, Campagna M-C, Wadhwa R, Blum MA, et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. Journal of clinical oncology. 2013;31(34):4306.
  10. Cheedella N, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T,,,Sudo K, et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Annals of Oncology. 2012;24(5):1262-6.

須藤 一起 医師が治験責任医師である治験一覧(実施中のもの)